Navigation Links
Stanford-led study disproves link between genetic variant, risk of coronary artery disease
Date:10/7/2010

erstandably great desire to use the information about human genetics that's been amassing since the sequencing of the human genome 10 years ago, said Quertermous, who has worked in the field for more than 20 years. "It's something I've been waiting for, for a long time."

That's because the well-known risk factors for atherosclerosis, such as high cholesterol, smoking, diabetes and high blood pressure, appear to account for only about half the variation of rates of coronary disease observed in human populations. The balance of variation is likely explained by a combination of inherited variants in or near genes that are important in the pathogenesis of disease in addition to other unrecognized, adverse environmental exposures.

"Using genetics to help improve our ability to predict coronary disease is particularly important because we have several different classes of drugs at our disposal that can substantially reduce the risk of heart attacks" said Assimes. "But we still need to be careful about what we put into practice and not get carried away too quickly. We know from previous experience that a positive association between a genetic variant and a common disease, such as coronary disease, needs to be consistently observed in many human population studies before it can be believed."

In fact, Quertermous points out that even for the roughly one dozen genetic markers that have been successfully validated to date, evidence to support their use in clinical practice is lacking. However, this situation will likely change in the near future as researchers reliably identify more genetic markers.

The data collections used in this study were supported by more than 30 institutions including government and nonprofit agencies and the following companies: Astra Zeneca, Berlin Chemie, Boots Healthcare, deCODE genetics, Glaxo-Smith-Kline, McNeil Pharma (former Woelm Pharma), MSD Sharp & Dohme and Pfizer.


'/>"/>

Contact: Susan Ipaktchian
susani@stanford.edu
650-725-5375
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Stanford-led team validates, extends fMRI research on brain activity
2. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
3. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
4. TV drama can be more persuasive than news program, study finds
5. Study carried out into biological risks of eating reptiles
6. Neuroimaging study may pave way for effective Alzheimers treatments
7. Study finds racial gaps continue in heart disease awareness
8. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
9. First blinded study of venous insufficiency prevalence in MS shows promising results
10. Soothing infants with food focus of childhood obesity study
11. People with anxiety disorder less able to regulate response to negative emotions, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... “Today, we introduce our new items ... over the world. All these models are offered at ... the UK market,” says the CEO of the company. ... women’s special occasion outfits. , Ladies have to find ... is one of the best choices for many ladies ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key ... provides value, in millions of US dollars, volume (in ... segments – Rigid Non-Video Sinuscopes. , The report also ... of these market categories, and global corporate-level profiles of ... deals related to the Sinuscopes market wherever available. , ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... of two titles, Journal of Analytical Toxicology ( JAT ... from Preston Publications, in a transaction managed by DeSilva+Phillips. The ... STM journal list published by OUP. "We are ... two titles. They have a rich history and we look forward ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- The ... a handy jet at your disposal, but the job also comes ... your life? Maybe not, new research suggests. The data showed ... years off their lives due to the effects of time spent ...
... HOBOKEN, NJ Keeping your brain in shapeno sweat. ... diet is just as important to maintaining mental performance ... are an easy, effective way to manage mental focus, ... antioxidant plant extract from the bark of the French ...
... depressive symptoms following birth also reported intimate partner violence finds ... An International Journal of Obstetrics and Gynaecology . The ... depressive symptoms first reported this at six months after birth ... emotional abuse) in the perinatal period is associated with a ...
... , TUESDAY, Dec. 6 (HealthDay News) -- New ... and when women with certain breast cancers will experience ... forms of breast cancer, are slated to be presented ... The research also revealed that genetic data gleaned ...
... in India are too poor to afford pacemakers. But a ... the devices and implanting them in Indian patients "is very ... Medical Center is a co-author of the study, published online ... . Kulkarni helped conduct the research before coming to Loyola ...
Cached Medicine News:Health News:Oxford University Press acquires 2 journals from Preston Publications 2Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: